Pathology Grand Rounds - New Perspectives on RAS Signaling in Cancer

At the conclusion of this activity, learners should be able to:

* Describe clinical trial data showing variation in how RAS mutant cancers respond to treatment

* Describe ongoing studies subclassifying RAS mutants into those that are biomarkers for EGFR inhibitor sensitivity and for EGFR inhibitor resistance

* Identify computational simulations as an emerging computational tool for studying pathogenic mutations and their response to treatment